Company intelligence / Profile preview

EnnoDC

Paris area likely, Île-de-France, Franceennodc.com ↗

Ownership: Private
Development stage: Phase 1

Overview

EnnoDC has developed a first-in-class dendritic cell-targeting immunotherapy platform, with its lead asset CD40HVac in Phase I/IIa trials for HPV16+ oropharyngeal cancer. The technology has also entered clinical development for infectious diseases such as HIV and COVID. The approach aims to deliver more targeted immune responses by directly stimulating dendritic cells, potentially reducing side effects and improving efficacy compared to existing therapies.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Fusion proteinsMonoclonal antibodies
Industry: Biotech

Drug pipeline

5 assets

CD40.HVac

4 more assets in the full pipeline.

Request access →

Partnerships

Baylor Institute for Immunology Research, Dallas TXMoffitt Cancer Center, USGustave Roussy Cancer Campus, FranceParis Saclay Cancer Cluster support

Beyond the preview

Go deeper on EnnoDC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EnnoDC.

Explore the full profile